Ulisse BioMed

Executive Summary

Ulisse BioMed, now rebranded as Helyx Industries, is an Italian biotechnology company founded in 2016 and headquartered in Trieste. The company provides comprehensive molecular biology solutions through three integrated divisions: Hyris (PCR and diagnostics), Vytro (next-generation sequencing), and Mytho (proprietary platform). With a focus on RNA-based therapeutics and diagnostics, Helyx aims to bridge the gap between research and clinical applications. The company is privately held and has not disclosed financing details, but its rebranding signals a strategic shift toward unifying its technologies under a single identity to capture broader market opportunities in precision medicine and infectious disease testing. By leveraging its proprietary platform, Helyx seeks to differentiate itself in the competitive molecular diagnostics and RNA therapeutics landscape, particularly in the European market where it has established a presence.

Upcoming Catalysts (preview)

• Q4 2026Launch of new multiplex PCR diagnostic panel70% success
• Q2 2027Partnership for RNA-based therapeutic delivery50% success
• Q3 2026Series A funding round closure65% success